Vitamin E
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Vitamin E
- Vitamin E: From Parenteral Nutrition Vitamin Supply to Inborn Disorder of Bilirubin Metabolism
Vitamin E: From Parenteral Nutrition Vitamin Supply to Inborn Disorder of Bilirubin Metabolism
One-Sentence Summary
Vitamin E is a fat-soluble vitamin. In South Africa it is registered mainly as a component of parenteral nutrition products (e.g. Vitalipid novum), and no approved indication text is recorded in the registration data. The TxGNN model predicts it may be useful for inborn disorder of bilirubin metabolism. Only 3 clinical trials and 2 publications were retrieved for this prediction, and none of the trials tests vitamin E, so the prediction is model-based only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data (products are parenteral nutrition and vitamin-containing infusions) |
| Predicted New Indication | Inborn disorder of bilirubin metabolism |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Vitamin E is a lipid-soluble antioxidant and membrane stabiliser. It may offset oxidative injury and fat-soluble vitamin deficiency in cholestatic or hyperbilirubinaemic states.
This link is generic and not specific to inherited bilirubin disorders. The prediction appears to come from knowledge-graph proximity between vitamin E and cholestatic or hyperbilirubinaemic conditions. None of the retrieved trials tests vitamin E, so no disease-specific mechanism is supported by the data.
The related but broader label “bilirubin metabolism disease” (rank 2) has more supporting material. This includes a 1979 study of intramuscular vitamin E in preterm infants with neonatal bilirubinaemia, and a Phase 4 randomised trial of vitamin E in fatty liver disease. The evidence is still indirect and does not establish benefit in a primary bilirubin disorder.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01556906 | Phase 2 | Completed | 6 | Open-label dose escalation of lomitapide in homozygous familial hypercholesterolaemia. Not vitamin E, so no drug-specific evidence. |
| NCT06465810 | N/A | Recruiting | 1,850 | Real-world observational study of transthyretin amyloidosis. No vitamin E arm. |
| NCT03115086 | N/A | Active, not recruiting | 55 | Post-marketing registry of cholic acid (Cholbam). No vitamin E intervention. |
No SANCTR or PACTR registrations were found in the data provided.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 803225 | 1975 | Review | N Engl J Med | Review of neonatal nonhemolytic jaundice. No abstract is available and vitamin E is not shown to be assessed. |
| 7915305 | 1994 | Case report | J Pediatr | 3β-hydroxy-C27-steroid dehydrogenase/isomerase deficiency as a cause of progressive intrahepatic cholestasis. Bile acid synthesis defect, not a vitamin E study. |
South Africa Market Information
Approved indication text is not listed for these registrations. Essential Medicines List status is not available in the data provided.
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Z/22.1/236 | Vitalipid novum adult 10ml | Infusion |
| 30/22.1/0201 | Vitalipid novum infant 10ml | Infusion |
| L/24/329 | Dextrose 20% in water 500ml | Infusion |
| Exclusion under Section 36 & Section 14 | ITN neonatal TPN 150ml | TPN |
| Exclusion under Section 36 & Section 14 | ITN baby 150ml | TPN |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug interaction records were found in the query.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there is no vitamin E–specific clinical evidence for inherited bilirubin disorders (L5). The retrieved trials test other agents, and the literature consists of one review and one case report on unrelated aetiologies.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications. This is a blocking gap that prevents safety screening.
- Mechanism of action data, e.g. from DrugBank.
- A specific sub-indication, since the disease label is broad and mixes heterogeneous conditions. Neonatal or cholestatic hyperbilirubinaemia (rank 2 evidence) would be a more testable starting point.
- Any interventional human data on vitamin E in these conditions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.